RA drugs under the microscope: which one keeps you stronger?

NCT ID NCT07182630

Not yet recruiting Knowledge-focused Sponsor: Firat University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at how two types of rheumatoid arthritis (RA) drugs—anti-TNF-α and non-TNF-α—affect patients' aerobic capacity, muscle strength, fatigue, and heart disease risk factors. Researchers will measure oxygen use during exercise, muscle strength, and disease activity in 40 adults aged 18-65 who have been on these drugs for 1-3 years. The goal is to understand which treatment better supports physical fitness and overall health in RA patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: anti-TNF-α and non-TNF-α drugs
What this could lead to: If successful, this study could help doctors choose RA treatments that better preserve patients' physical fitness and reduce heart disease risk.
What could go wrong: This is a small, early-stage observational study with only 40 participants, so results may not apply to all RA patients. It measures changes but does not test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS (RA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS (RA)

Contacts and locations

Locations

Fırat University

Elâzığ, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.